Gregory L. Weaver, Chief Financial Officer at Altimmune, Inc. (ALT), bought 10,000 shares at $3.15 ($31K) on 2026-04-01, disclosed to the SEC on 2026-04-01.
CFO Gregory L. Weaver purchased 10,000 shares of Altimmune for $31,500, signaling confidence in the company's financial health and clinical pipeline. This trade occurs as the stock trades near its 52-week low, potentially offering a contrarian entry point for investors betting on pemvidutide's success.
ALT is down 25% over the last 30 days and 34.25% over the past year, trading 59.64% below its 52-week high of $7.73.
Something here stands out, but not much.
| Filing → |
| ATOS | SELL | 2023-11-17 | $33K | — | Filing → |
| ATOS | BUY | 2023-06-20 | $49K | — | Filing → |
| ATOS | SELL | 2021-07-07 | $1.2M | — | Filing → |